CytoImmune Therapeutics Announces Appointment of Industry Veteran Douglas E. Williams, Ph.D., to Board of Directors

MONROVIA, Calif.: MONROVIA, Calif., June 15, 2021 /PRNewswire/ -- CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, announced today the appointment of Douglas E. Williams, Ph.D., to its Board of Directors, effective as of June 15, 2021. Dr. Williams brings decades of...

Click to view original post